Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes.
African horse sickness virus (AHSV), an orbivirus in the Reoviridae family with nine different serotypes, causes devastating disease in equids. The virion particle is composed of seven proteins organized in three concentric layers, an outer layer made of VP2 and VP5, a middle layer made of VP7, and inner layer made of VP3 that encloses a replicase complex of VP1, VP4, and VP6 and a genome of 10 double-stranded RNA segments. In this study, we sought to develop highly efficacious candidate vaccines against all AHSV serotypes, taking into account not only immunogenic and safety properties but also virus productivity and stability parameters, which are essential criteria for vaccine candidates. To achieve this goal, we first established a highly efficient reverse genetics (RG) system for AHSV serotype 1 (AHSV1) and, subsequently, a VP6-defective AHSV1 strain in combination with in trans complementation of VP6. This was then used to generate defective particles of all nine serotypes, which required the exchange of two to five RNA segments to achieve equivalent titers of particles. All reassortant-defective viruses could be amplified and propagated to high titers in cells complemented with VP6 but were totally incompetent in any other cells. Furthermore, these replication-incompetent AHSV particles were demonstrated to be highly protective against homologous virulent virus challenges in type I interferon receptor (IFNAR)-knockout mice. Thus, these defective viruses have the potential to be used for the development of safe and stable vaccine candidates. The RG system also provides a powerful tool for the study of the role of individual AHSV proteins in virus assembly, morphogenesis, and pathogenesis.



African horse sickness virus is transmitted by biting midges and causes African horse sickness in equids, with mortality reaching up to 95% in naive horses. Therefore, the development of efficient vaccines is extremely important due to major economic losses in the equine industry. Through the establishment of a highly efficient RG system, replication-deficient viruses of all nine AHSV serotypes were generated. These defective viruses achieved high titers in a cell line complemented with VP6 but failed to propagate in wild-type mammalian or insect cells. Importantly, these candidate vaccine strains showed strong protective efficacy against AHSV infection in an IFNAR(-/-) mouse model.
Department of Pathogen Molecular Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Valeria
V
Lulla
Department of Pathogen Molecular Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Aleksei
A
Lulla
Institute of Diagnostic Virology, Friedrich-Loeffler Institut, Greifswald, Germany.
Kerstin
K
Wernike
Institute of Diagnostic Virology, Friedrich-Loeffler Institut, Greifswald, Germany.
Andrea
A
Aebischer
Institute of Diagnostic Virology, Friedrich-Loeffler Institut, Greifswald, Germany.
Martin
M
Beer
Department of Pathogen Molecular Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom polly.roy@lshtm.ac.uk.
Polly
P
Roy
D000355:African Horse Sickness / Q000517:prevention & control*; D000356:African Horse Sickness Virus / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D000818:Animals; D003673:Defective Viruses / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D004195:Disease Models, Animal; D017353:Gene Deletion; D051379:Mice; D018345:Mice, Knockout; D059386:Reverse Genetics; D065288:Serogroup; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism*; D014771:Virion / Q000378:metabolism*; D019065:Virus Assembly; D014779:Virus Replication
D014765:Viral Vaccines